Invest-NL to invest in ONWARD

An international life sciences company based in Eindhoven, ONWARD develops neurostimulation therapies for spinal injury patients. These therapies are designed to reactivate arm-hand coordination and mobility, as well as restore vital bodily functions such as blood pressure and bladder function.

The current investment round will enable ONWARD to further refine and clinically validate these two cutting-edge technology-based therapies. Both the external (ARCEX) and the implantable (ARCIM) systems are designed to improve movement and even restore mobility in spinal injury sufferers through targeted, specifically programmed neurostimulation of the spine. This radically improves their quality of life and levels of independence, thereby reducing the costs of medical care.

Both technology-based platforms have been awarded Breakthrough Device Designation by the US Food and Drug Administration. The external system (ARC-EX) is also part of a crucial clinical trial, Up-LIFT.

“The ground-breaking technology of promising neurostimulation therapies has the potential to dramatically improve the quality of life of spinal injury patients,” said Leo Holwerda, Capital Director at Invest-NL. “The present investment round for ONWARD shows that existing and new investors alike are confident that the company has the technology, skills and ambition to grow further and secure a leading position in the market.”

“We are passionate about developing cutting-edge research and transferring it from laboratory to market,” added Dave Marver, CEO of ONWARD. “This investment will support ONWARD in its commitment to help spinal injury patients improve their lives in every possible way.”